← Back to patent-cliff list
IPP-204106
Tier C — Watch / tradeIPP-204106
Immupharma Plc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NCL
Indications (approved)：Neoplasm, Solid tumour
Regional status
US
-
EU
No progress
2012-07-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of IPP-204106?
Approved indications include: Neoplasm, Solid tumour.
When does the IPP-204106 patent expire?
No public expiry year is available for IPP-204106 yet; this page updates once verified.
How do I get a quote for IPP-204106 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-18